Alkem Laboratories reports 13.5% revenue growth for FY26
The company detailed its Q4 and full-year performance, providing therapy-wise market share data and a remediation update on the Daman facility.
— 1 earlier story on Alkem Laboratories Ltd. →What's new
- Alkem reported 13.5% revenue growth from gains in India and international markets.
- The presentation provides therapy-wise market share data and US FDA compliance status.
- Management issued a remediation update regarding the Daman manufacturing facility.
Why this matters
This data allows for precise institutional modeling. It confirms the company's growth is balanced across both domestic and international operations.
What we're watching
- Progress on the Daman facility remediation efforts.
- Sustainability of double-digit growth in the Indian Pharmaceutical Market.
- Any further updates on US FDA inspection outcomes.
The full read
Alkem Laboratories released its investor presentation for Q4FY26 and FY26. Revenue increased 13.5% year-on-year. Growth is broad-based, with double-digit contributions from both its domestic Indian Pharmaceutical Market and international operations.
It is routine.
The filing offers therapy-wise market share data and a status report on the company's US FDA compliance network, while management provided a specific remediation update for the Daman facility to clarify the current standing of their manufacturing infrastructure. This document is a standard, backward-looking disclosure containing no surprises that would force a revaluation of the company's current position, serving only as a technical tool for institutional modeling.
Questions answered
- What drove Alkem's revenue growth in FY26?
- Growth of 13.5% came from double-digit gains in both the Indian Pharmaceutical Market and international segments.
- Does the presentation provide details on manufacturing compliance?
- Yes, it includes the status of US FDA compliance across the manufacturing network, including a remediation update for the Daman facility.
- Does this filing contain unexpected material information?
- No. The document is a routine supplemental disclosure covering previously reported financial performance.
Story so far
All notes on ALKEM →- 28 May 2026 · 1:42 PM IST Alkem Laboratories reports 13.5% revenue growth for FY26
- today Alkem Laboratories reports steady growth in line with expectations